Newleos Therapeutics

Dedicated to providing a new dawn or "eos" for patients with mental health conditions by developing next generation, first- and best-in-class therapies.

[Newleos Therapeutics @NewleosTx]

Dr. Lago will also present poster W10 on May 27 on the completed NTX-1472 Ph1 program and design of our ongoing SOAR Ph2 study. With #NTX1472 and #NTX1955, we are advancing differentiated therapeutic candidates for #AnxietyDisorders. #ClinicalTrials https://t.co/OB5xCLdWPY

[Newleos Therapeutics @NewleosTx]

On May 26 at #ASCP2026 in Miami, Tiffany Lago will present on the clinical advancement of NTX-1472, our V1aR antagonist in development for #SocialAnxietyDisorder. Targeting V1aR has the potential to address the neural circuits driving SAD. #MentalHealth https://t.co/blpc3HpEu7

[Newleos Therapeutics @NewleosTx]

With NTX-2001 now in Phase 1b, Newleos has three programs in the clinic: #NTX1955 (Phase 1b, GAD), #NTX1472 (Phase 2 SOAR, SAD), and #NTX2001 (Phase 1b, AUD). #Neuropsychiatry #MentalHealth #ClinicalTrials

[Newleos Therapeutics @NewleosTx]

We recently dosed the first participant in a Phase 1b study of #NTX2001, Newleos’ TAAR1 partial agonist being developed for alcohol use disorder. NTX-2001 is the first TAAR1 agonist to be clinically studied in AUD. https://t.co/x8acHKMp6Z #SubstanceUseDisorders #CNS

[Newleos Therapeutics @NewleosTx]

We’ve dosed the first participant in our 3rd Phase 1b study of #NTX1955, our investigational GABAA-γ1 PAM for generalized #AnxietyDisorder. The U.K. study joins 2 EU Phase 1b trials advancing toward a Phase 2 efficacy study. https://t.co/BV8xdxPZET
#MentalHealth #ClinicalTrials

[Newleos Therapeutics @NewleosTx]

Newleos attended @Dup15qAlliance's Believe in a Cure Gala, supporting research into #Dup15q syndrome. #NTX1511 is being studied as a potential therapy targeting the underlying biology of this rare neurodevelopmental disorder. #RareDisease #CNS🔗https://t.co/8TEhkU3rtj

[Newleos Therapeutics @NewleosTx]

We’re honored to be named one of the top life sciences startups to watch in @BioSpace’s NextGen Class of 2026. Proud to advance new treatment options for #MentalHealth, including our clinical-stage programs in #anxietydisorders.
🔗 https://t.co/gR1X60RvLZ

[Newleos Therapeutics @NewleosTx]

Information on the SOAR Phase 2 study of NTX-1472 is available at: https://t.co/CSW5zrxFp7

[Newleos Therapeutics @NewleosTx]

Newleos leaders Tiffany Lago, MD, & Federico Bolognani, MD, PhD, published commentary in Current Issues in Molecular Biology on vasopressin 1a (V1a) receptor antagonists and their potential role in treating #AnxietyDisorders. @CIMB_MDPI @MDPIOpenAccess 🔗https://t.co/N4NlytnV4L

[Newleos Therapeutics @NewleosTx]

The publication coincides with an important Newleos milestone: first participant dosed in our SOAR Phase 2 study of NTX-1472, a selective, brain-penetrant V1a receptor antagonist for #SocialAnxietyDisorder (SAD).
🩺NCT07323784
#Neuropsychiatry #CNS #ClinicalTrials

[Newleos Therapeutics @NewleosTx]

A downloadable reprint is available on the News page of Newleos' website: https://t.co/txNDDsLmD8

[Newleos Therapeutics @NewleosTx]

Milestone at Newleos: first participant dosed in the SOAR Phase 2 study of #NTX1472 for #SocialAnxietyDisorder. Alongside #NTX1955 for #GeneralizedAnxietyDisorder, our anxiety programs are designed to precisely target neural circuits that drive anxiety. https://t.co/gaI85irJbm

[Newleos Therapeutics @NewleosTx]

Welcome to our newly appointed President and CEO, Tim Noyes!
His leadership will help drive our mission to develop next-generation #neuropsychiatric therapies for patients who have long been underserved. https://t.co/gaI85irblO #TeamNewleos #Biotech #MentalHealth

[Newleos Therapeutics @NewleosTx]

Congratulations to our Founding CEO, David Donabedian, named one of @GoldmanSachs’ Most Exceptional Entrepreneurs of 2025!
A well-earned recognition of visionary leadership and commitment to advancing next-generation #biotech innovations. #GSInnovators https://t.co/gaI85irblO

[Newleos Therapeutics @NewleosTx]

Progress across our #neuropsychiatry pipeline: ✅2nd NTX-1955 Phase 1b study initiated in EU for generalized #anxiety ✅U.S. FDA IND clearance for NTX-1472 Phase 2 in social anxiety. Novel mechanisms address patients underserved by current treatments. https://t.co/gaI85irJbm

[Newleos Therapeutics @NewleosTx]

Today, we shared data supportive of #NTX1955 at #WFSBP2025: Selective modulation of GABAA-γ1 showed preclinical efficacy in anxiety models without benzodiazepine-like side effects. https://t.co/gaI85irJbm #AnxietyDisorders #CNS #Biotechnology

[Newleos Therapeutics @NewleosTx]

Welcome Dr. Stephen Brannan to our Board of Directors. The former CMO of Karuna joins at a time of growing momentum as our clinical candidate for generalized #AnxietyDisorder #NTX1955 enters Phase 1b trials in the EU. https://t.co/gaI85irblO
#MentalHealth #CNS #biotech

[Newleos Therapeutics @NewleosTx]

Welcome to the inaugural members of our Clinical Advisory Board. The guidance from leading experts in #psychiatry & #neuroscience will support our development of candidates targeting #AnxietyDisorders, including #NTX1955 & #NTX1472. https://t.co/gaI85irblO #MentalHealth #CNS

[Newleos Therapeutics @NewleosTx]

We are delighted to welcome an accomplished group of professionals to Newleos. The collective experience and leadership of our expanded team enhances our operational capabilities and supports the advancement of our clinical-stage neuropsychiatric programs. https://t.co/gaI85irblO

[Boston Business Journal @BosBizJournal]

A Boston VC firm is launching a new neuroscience company with a $93M investment that aims to treat disorders including anxiety and substance use without the side effects seen in already available medications. https://t.co/zU155T4GJl